- Home
- ERIE vs MDGL Comparison
ERIE vs MDGL Comparison
Compare ERIE & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERIE | MDGL |
|---|---|---|
| Founded | 1925 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 11.5B |
| IPO Year | 2012 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ERIE | MDGL |
|---|---|---|
| Price | $256.32 | $453.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $685.78 |
| AVG Volume (30 Days) | 130.6K | ★ 266.9K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 491.00 | N/A |
| Revenue | ★ $1,691,774,000.00 | $180,133,000.00 |
| Revenue This Year | $2.51 | $59.57 |
| Revenue Next Year | N/A | $38.84 |
| P/E Ratio | $0.50 | ★ N/A |
| Revenue Growth | ★ 5.96 | N/A |
| 52 Week Low | $204.63 | $393.61 |
| 52 Week High | $330.54 | $615.00 |
Technical Indicators
Market Signals| Indicator | ERIE | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 67.14 | 34.11 |
| Support Level | $248.23 | $416.21 |
| Resistance Level | $262.47 | $546.29 |
| Average True Range (ATR) | 6.79 | 17.78 |
| MACD | 3.93 | -1.00 |
| Stochastic Oscillator | 98.76 | 16.77 |
Price Performance
Historical ComparisonAbout ERIE Erie Indemnity Company
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.